Transcatheter aortic valve implantation (TAVI) yielded inconclusive and inconsistent cost-effectiveness results across 33 economic evaluations, ranging from dominant to dominating.
Systematic Review (n=33)
Is transcatheter aortic valve implantation (TAVI) cost-effective across all risk categories?
The cost-effectiveness of TAVI remains inconclusive and highly sensitive to modeling variables, necessitating further research and individualized decision-making.
Objective: The scope of this systematic review is to update the existing body of evidence regarding the cost-effectiveness of transcatheter aortic valve implantation, stratified across all risk categories, and to assess their methodological quality. Methods: A systematic review was performed including published cost-effectiveness analyses of heart valve implantations. The quality was assessed with the Quality of Health Economics Tool. Results: We identified 33 economic evaluations of transcatheter aortic heart valve implantations. Results were not consistent, ranging from dominant to dominating. Moreover, the models were sensitive to an array of variables. The methodological quality of the studies was good. Conclusion: This systematic review led to inconclusive and inconsistent results pertinent to the economic profile of TAVI technology. It also highlighted areas which merit further research regarding the pillars of cost-effectiveness analysis such as modeling, the extrapolation of available data and the uncertainty of the evidence. A thorough assessment of the patient should proceed any decision-making.
Panagiotis Petrou (Wed,) conducted a systematic review in Aortic valve disease (n=33). Transcatheter aortic valve implantation (TAVI) was evaluated on Cost-effectiveness. Transcatheter aortic valve implantation (TAVI) yielded inconclusive and inconsistent cost-effectiveness results across 33 economic evaluations, ranging from dominant to dominating.